Surrogate molecular classification of LAR breast cancer in routine workflow

in Endocrine-Related Cancer
Authors:
Nelson Rangel Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia

Search for other papers by Nelson Rangel in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0002-9709-2196
,
Laura Serrao Department of Medical Sciences, University of Turin, Turin, Italy

Search for other papers by Laura Serrao in
Current site
Google Scholar
PubMed Close
,
Giulia Capella Department of Medical Sciences, University of Turin, Turin, Italy

Search for other papers by Giulia Capella in
Current site
Google Scholar
PubMed Close
,
Giulia Orlando Department of Oncology, University of Turin, Turin, Italy

Search for other papers by Giulia Orlando in
Current site
Google Scholar
PubMed Close
,
Federica Ragno Department of Medical Sciences, University of Turin, Turin, Italy

Search for other papers by Federica Ragno in
Current site
Google Scholar
PubMed Close
,
Milena Rondón-Lagos School of Biological Sciences, Universidad Pedagógica y Tecnológica de Colombia, Tunja, Colombia

Search for other papers by Milena Rondón-Lagos in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0002-3160-9316
,
Jasna Metovic Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Search for other papers by Jasna Metovic in
Current site
Google Scholar
PubMed Close
,
Paola Cassoni Department of Medical Sciences, University of Turin, Turin, Italy

Search for other papers by Paola Cassoni in
Current site
Google Scholar
PubMed Close
, and
Isabella Castellano Department of Medical Sciences, University of Turin, Turin, Italy

Search for other papers by Isabella Castellano in
Current site
Google Scholar
PubMed Close

Correspondence should be addressed to N Rangel: rangeljne@javeriana.edu.co or to I Castellano: isabella.castellano@unito.it
DOI:
https://doi.org/10.1530/ERC-24-0316
Volume/Issue:
Volume 32: Issue 6
Article Type:
Research Article
Article ID:
e240316
Online Publication Date:
05 May 2025
Copyright:
© the author(s) 2025
Restricted access
Rent on DeepDyve

Sign up for journal news

Triple negative breast cancer (TNBC) is a heterogeneous disease, considered the most aggressive among all diagnosed breast cancers. The luminal androgen receptor (LAR) category has been recognized as a distinct entity (subtype), observed in around 15% of the TNBCs, but currently there is no complete overlap to clearly distinguish them from the other TNBC counterparts. With the aim to better establish morphological, immunohistochemical and molecular features of LAR tumors, gene and signatures expression was evaluated in 42 well-characterized TNBCs. Furthermore, protein expression of a panel of several markers (AR, FOXA1, CK5/6, p63, GCDFP-15 and FGFR4) was also studied. Compared with non-LAR cases, LAR tumors often display low tumor grade, reduced levels of Ki-67, total absence of CK5/6 and p63 basal markers expression, but show high positivity for AR, FOXA1 and FGFR4. Regarding molecular assessment, LAR tumors were characterized by higher scores of gene signatures associated with AR, FOXA1 and ERBB2, while showed lower scores of signatures related to BC proliferation, CDK6, BRCAness and p53. Our results suggest that among TNBC, LAR cases are associated with features indicative of a less aggressive tumor behavior. Accurate distinction of this TNBC subtype is important since they are resistant to chemotherapy and may potentially benefit from tailored-therapeutical approaches. Specifically, therapies targeting AR together to additional proteins, such as FGFR4, FOXA1 or CDK6, may represent future directions in the treatment approach of LAR tumors.

Supplementary Materials

Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 13 13 12
PDF Downloads 19 19 18

 

  • Collapse
  • Expand
Print ISSN:
1351-0088
Online ISSN:
1479-6821
Copyright:
© the author(s) 2025
Article ID:
e240316
Received Date:
09 Dec 2024
Rev-recd:
10 Apr 2025
Accepted Date:
23 Apr 2025
Print Publication Date:
01 Jun 2025
Online Publication Date:
05 May 2025
Keywords:
breast cancer; molecular subtypes; luminal androgen receptor; triple negative breast cancer; fibroblast growth factor receptor

  • Asghar US , Barr AR , Cutts R , et al. 2017 Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res 23 5561–5572. (https://doi.org/10.1158/1078-0432.CCR-17-0369)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Burstein MD , Tsimelzon A , Poage GM , et al. 2015 Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21 1688–1698. (https://doi.org/10.1158/1078-0432.CCR-14-0432)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Cha YJ , Jung W-H & Koo JS 2012 The clinicopathologic features of molecular apocrine breast cancer. Korean J Pathol 46 169. (https://doi.org/10.4132/KoreanJPathol.2012.46.2.169)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Coates AS , Winer EP , Goldhirsch A , et al. 2015 Tailoring therapies-improving the management of early breast cancer: st gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26 1533–1546. (https://doi.org/10.1093/annonc/mdv221)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Daemen A & Manning G 2018 HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. Breast Cancer Res 20 8. (https://doi.org/10.1186/s13058-018-0933-y)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Giovannelli P , Di Donato M , Galasso G , et al. 2018 The androgen receptor in breast cancer. Front Endocrinol 9 492. (https://doi.org/10.3389/fendo.2018.00492)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Giovannelli P , Di Donato M , Auricchio F , et al. 2019 Androgens induce invasiveness of triple negative breast cancer cells through AR/Src/PI3-K complex assembly. Sci Rep 9 4490. (https://doi.org/10.1038/s41598-019-41016-4)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Goldhirsch A , Wood WC , Coates AS , et al. 2011 Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22 1736–1747. (https://doi.org/10.1093/annonc/mdr304)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Goldhirsch A , Winer EP , Coates AS , et al. 2013 Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24 2206–2223. (https://doi.org/10.1093/annonc/mdt303)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Hammond MEH , Hayes DF , Dowsett M , et al. 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28 2784–2795. (https://doi.org/10.1200/JCO.2009.25.6529)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Hartung C , Porsch M , Stückrath K , et al. 2021 Identifying high-risk triple-negative breast cancer patients by molecular subtyping. Breast Care 16 637–647. (https://doi.org/10.1159/000519255)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Hickey TE , Robinson JLL , Carroll JS , et al. 2012 Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 26 1252–1267. (https://doi.org/10.1210/me.2012-1107)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Hilborn E , Gacic J , Fornander T , et al. 2016 Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer. Br J Cancer 114 248–255. (https://doi.org/10.1038/bjc.2015.464)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Hudis CA , Barlow WE , Costantino JP , et al. 2007 Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25 2127–2132. (https://doi.org/10.1200/JCO.2006.10.3523)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Ibrahim A , Toss MS , Alsaleem M , et al. 2024 Novel 2 gene signatures associated with breast cancer proliferation: insights from predictive differential gene expression analysis. Mod Pathol 37 100403. (https://doi.org/10.1016/j.modpat.2023.100403)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Katoh M 2019 Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 16 105–122. (https://doi.org/10.1038/s41571-018-0115-y)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Khadela A , Chavda VP , Soni S , et al. 2022 Anti-androgenic therapies targeting the luminal androgen receptor of a typical triple-negative breast cancer. Cancers 15 233. (https://doi.org/10.3390/cancers15010233)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Lehmann BD , Bauer JA , Chen X , et al. 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121 2750–2767. (https://doi.org/10.1172/JCI45014)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Lehmann BD , Pietenpol JA & Tan AR 2015 Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book 35 e31–e39. (https://doi.org/10.14694/EdBook_AM.2015.35.e31)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Lehmann BD , Jovanović B , Chen X , et al. 2016 Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One 11 e0157368. (https://doi.org/10.1371/journal.pone.0157368)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Lehmann-Che J , Hamy AS , Porcher R , et al. 2013 Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 15 R37. (https://doi.org/10.1186/bcr3421)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Di Leone A , Fragomeni SM , Scardina L , et al. 2021 Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer. Eur Rev Med Pharmacol Sci 25 1910–1915. (https://doi.org/10.26355/eurrev_202102_25087)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Levine KM , Ding K , Chen L , et al. 2020 FGFR4: a promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther 214 107590. (https://doi.org/10.1016/j.pharmthera.2020.107590)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Liman A , Kabir B , Abubakar M , et al. 2022 Triple-negative breast cancer (TNBC) and its luminal androgen receptor (LAR) subtype: a clinicopathologic review of cases in a university hospital in Northwestern Nigeria. Niger J Clin Pract 25 97–104. (https://doi.org/10.4103/njcp.njcp_437_20)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Liu Y , Nekulova M , Nenutil R , et al. 2020 ∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER+ and HER2+ breast cancers. J Pathol Clin Res 6 83–93. (https://doi.org/10.1002/cjp2.149)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Marchetti P , Cannita K , Ricevuto E , et al. 2003 Prognostic value of p53 molecular status in high-risk primary breast cancer. Ann Oncol 14 704–708. (https://doi.org/10.1093/annonc/mdg197)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Masuda H , Baggerly KA , Wang Y , et al. 2013 Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19 5533–5540. (https://doi.org/10.1158/1078-0432.CCR-13-0799)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Migliaccio A , Di Domenico M , Castoria G , et al. 2005 Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 65 10585–10593. (https://doi.org/10.1158/0008-5472.CAN-05-0912)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Mills AM , Gottlieb CE , Wendroth SM , et al. 2016 Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor–positive subset of triple-negative breast cancers. Am J Surg Pathol 40 1109–1116. (https://doi.org/10.1097/PAS.0000000000000671)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Mohammed AA , Elsayed FM , Algazar M , et al. 2020 Neoadjuvant chemotherapy in triple negative breast cancer: correlation between androgen receptor expression and pathological response. Asian Pac J Cancer Prev 21 563–568. (https://doi.org/10.31557/APJCP.2020.21.2.563)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Morris GJ , Naidu S , Topham AK , et al. 2007 Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. Cancer 110 876–884. (https://doi.org/10.1002/cncr.22836)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Prat A , Adamo B , Cheang MCU , et al. 2013 Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18 123–133. (https://doi.org/10.1634/theoncologist.2012-0397)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Rampurwala M , Wisinski KB & O’Regan R 2016 Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol 14 186–193.

  • Rangel N , Fortunati N , Osella-Abate S , et al. 2018 FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients. BMC Cancer 18 703. (https://doi.org/10.1186/s12885-018-4624-y)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Sapino A , Marchiò C , Senetta R , et al. 2006 Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449 288–296. (https://doi.org/10.1007/s00428-006-0233-2)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Stella S , Martorana F , Massimino M , et al. 2023 Potential therapeutic targets for luminal androgen receptor breast cancer: what we know so far. OncoTargets Ther 16 235–247. (https://doi.org/10.2147/OTT.S379867)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Sung H , Ferlay J , Siegel RL , et al. 2021 Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71 209–249. (https://doi.org/10.3322/caac.21660)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Thompson KJ , Leon-Ferre RA , Sinnwell JP , et al. 2022 Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer 4 zcac018. (https://doi.org/10.1093/narcan/zcac018)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Touat M , Ileana E , Postel-Vinay S , et al. 2015 Targeting FGFR signaling in cancer. Clin Cancer Res 21 2684–2694. (https://doi.org/10.1158/1078-0432.CCR-14-2329)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • VanArsdale T , Boshoff C , Arndt KT , et al. 2015 Molecular pathways: targeting the cyclin D–CDK4/6 axis for cancer treatment. Clin Cancer Res 21 2905–2910. (https://doi.org/10.1158/1078-0432.CCR-14-0816)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Vranic S , Schmitt F , Sapino A , et al. 2013 Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol 28 1393–1409. (https://doi.org/10.14670/HH-28.1393)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Vtorushin S , Dulesova A & Krakhmal N 2022 Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. J Zhejiang Univ Sci B 23 617–624. (https://doi.org/10.1631/jzus.B2200113)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Zagami P & Carey LA 2022 Triple negative breast cancer: pitfalls and progress. Npj Breast Cancer 8 95. (https://doi.org/10.1038/s41523-022-00468-0)

  • Zhao S , Ma D , Xiao Y , et al. 2020 Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist 25 e1481–e1491. (https://doi.org/10.1634/theoncologist.2019-0982)

    • PubMed
    • Search Google Scholar
    • Export Citation

  • Zhu Y , Wu J , Zhang C , et al. 2016 BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget 7 70113–70127. (https://doi.org/10.18632/oncotarget.12158)

    • PubMed
    • Search Google Scholar
    • Export Citation